

Adalimumab
Essential medicine status
General description

INN

Adalimumab

ATC codes

[L04AB04](#)

Medicine type

Biological agent

EML status history

First added in 2019 ([TRS 1021](#)) for [Rheumatoid arthritis](#)

Added in 2019 ([TRS 1021](#)) for [Axial spondyloarthritis](#)

Added in 2019 ([TRS 1021](#)) for [Juvenile idiopathic arthritis](#)

Added in 2019 ([TRS 1021](#)) for [Crohn disease site](#)

Added in 2025 ([TRS 1064](#)) for [Psoriasis of unspecified type](#)

Wikipedia

[Adalimumab](#)

DrugBank

[Adalimumab](#)

Recommendations

Section

Immunomodulators for non-malignant disease

- Parenteral > General injections > SC: 40 mg per 0.8 mL; 40 mg per 0.4 mL; 10 mg per 0.2 mL; 20 mg per 0.4 mL

Indications

[Rheumatoid arthritis](#) [Axial spondyloarthritis](#) [Crohn disease site](#)

Section

Medicines for juvenile joint diseases

- Parenteral > General injections > SC: 40 mg per 0.8 mL; 40 mg per 0.4 mL; 10 mg per 0.2 mL; 20 mg per 0.4 mL

Indications

[Juvenile idiopathic arthritis](#)

Section

Dermatological medicines > Medicines affecting skin differentiation and proliferation

- Parenteral > General injections > SC: 10 mg per 0.2 mL mL in pre-filled syringe or pre-filled pen.; 20 mg per 0.2 mL mL in pre-filled syringe or pre-filled pen.; 20 mg per 0.4 mL mL in pre-filled syringe or pre-filled pen.; 40 mg per 0.4 mL mL in pre-filled syringe or pre-filled pen.; 40 mg per 0.8 mL mL in pre-filled syringe or pre-filled pen.; 80 mg per 0.8 mL mL in pre-filled syringe or pre-filled pen.

Indications

[Psoriasis of unspecified type](#)